CD34 (CD34 molecule)

Both cases showed classic DFSP morphology and diffuse CD34 expression. These findings expand the molecular landscape of DFSP and illustrate convergent mechanisms of PDGFR-β activation achieved through diverse yet functionally equivalent genomic rearrangements.

Furthermore, we confirmed the specificity of circZEB1 expression to cases with SF3B1 mutations. We conclude that aberrant circRNA expression is found in MDS and displays associations with disease characteristics and patient outcomes.

Definitive diagnosis depends on histopathological and immunohistochemical confirmation. Complete surgical excision offers a favorable prognosis.

In this cohort, 5‑color flow cytometry provided practical MRD assessment in B‑ALL, whereas 10‑color flow cytometry offered greater immunophenotypic detail and improved recognition of low‑level residual disease. These findings support the routine use of flow cytometry‑based MRD evaluation alongside morphology for post‑induction response assessment and risk‑adapted management in B‑ALL.

The long disease-free interval raises the diagnostic dilemma of late recurrence versus a metachronous SFT, a distinction that remains challenging due to shared morphologic and molecular characteristics. This case underscores the limitations of metabolic imaging in indolent SFTs and highlights the importance of complete surgical resection and long-term, potentially lifelong, surveillance.

Diagnosis depends on histopathology and immunohistochemistry, particularly STAT6. Complete excision is usually curative, but long-term surveillance remains essential.

EGFR 19Del and 21L858R mutations are associated with distinct expression patterns of VEGFR1 and CD34, which may underlie differential responses to anti-angiogenic therapy and inform future combination treatment strategies.

(1) Metastatic or recurrent G-GIST; (2) Concurrent other malignancies; (3) Received neoadjuvant imatinib therapy; (4) Intraoperative conversion to laparotomy...Tumor size >5 cm was an independent risk factor for RFS (P<0.05). Comparing to the laparotomy, laparoscopic operation for G-GISTs had superior perioperative outcomes without compromising oncologic outcomes.

It is proposed that telocytes serve as key mediators of tissue organization and biomechanical signaling, contributing to a feedback loop that promotes tumor progression. Combining acinar architecture with stromal phenotyping provides a refined framework for understanding epithelial-stromal co-evolution in PCa.

Our findings indicate that ALK-rearranged mesenchymal neoplasms with fibrosarcoma-like features, particularly those associated with elevated mitotic activity or tumor necrosis, should be classified as high grade in pathology reports. In addition, this case also demonstrated that neoadjuvant therapy may be a better treatment strategy compared to upfront surgery for ALK-rearranged mesenchymal neoplasms with a relatively high tumor burden.

Targeted tyrosine kinase inhibitors (TKIs) have transformed GIST management, with imatinib as the foundational first-line therapy and subsequent agents, sunitinib, regorafenib, avapritinib, and ripretinib, addressing primary or secondary resistance driven by diverse mutational patterns. Emerging therapeutic directions include next-generation kinase inhibitors, heat shock protein inhibitors, immunotherapy, metabolic and epigenetic targeting, and biomarker-driven individualized treatment strategies. This review synthesizes contemporary advances in the histopathological, molecular, and therapeutic landscape of GISTs, emphasizing an integrated diagnostic approach and highlighting ongoing efforts to overcome therapeutic resistance and optimize personalized care.

The stability of the top three receptor-ligand complexes was validated through molecular dynamics simulations. Therefore, our findings could be a valuable resource for researchers and medical professionals, aiding in BC diagnosis and treatment.